Kannalife, a subsidiary of Neuropathix, Inc., is a pioneering biopharmaceutical company advancing globally patented, synthetic cannabinoid-inspired therapeutics for the treatment of neurodegenerative and neuropathic diseases. Headquartered at the Pennsylvania Biotechnology Center, Kannalife’s lead candidate, KLS-13019, targets key drivers of neuroinflammation and mitochondrial dysfunction, including mNCX-1, GPR55, and the NLRP3 inflammasome. The company’s innovation has been recognized through substantial non-dilutive funding, including a $1.5 million grant from The Michael J. Fox Foundation for Parkinson’s Research and $3.3 million from the NIH HEAL Initiative to support IND-enabling studies to advance KLS-13019 toward clinical trials.
Company Details
- Founded
- 2013
- Address
- 3805 Old Easton Rd, Doylestown,pennsylvania 18902,united States
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.kannalife.com
- HQ
- Doylestown, Pennsylvania
Kannalife, Inc. Questions
Kannalife, Inc.'s website is http://www.kannalife.com
Kannalife, Inc.'s LinkedIn profile is https://www.linkedin.com/company/kannalife
Kannalife, Inc.'s industry is
Pharmaceutical Manufacturing
Kannalife, Inc.'s top competitors are
Nephroceuticals,
Navrogen,
Axar Pharmaceuticals Private Limited,
Kannalife Sciences, Inc.,
Lexicon Pharmaceuticals, Inc.,
Neuropathix, Inc.,
Mid-Atlantic Biotherapeutics (Mabt),
Mcguff Compounding Pharmacy Services, Inc.,
Topchem Engineering Srl,
Kinetic Concepts Inc.
Kannalife, Inc.'s categories are Pharmaceutical Manufacturing
Kannalife, Inc.'s founding year is 2013
